Like us on Facebook!

Eosinophilic Esophagitis Trial

Eosiniphilic esophagitis (EoE) is defined as “a chronic, immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil predominant inflammation”( Liacouras et al., 2011).

EoE is considered a swallowing disorder. Clinical symptoms of EoE often vary by age, GWR upper GI Adam

  • Infants and toddlers present with feeding difficulties
  • School-aged children are more likely to present with vomiting or pain
  • Adolescents and adults present with dysphagia and food impaction.

When these symptoms are present, the diagnosis is confirmed by finding eosinophilic inflammation of 15 eosinophils/high-powered field (HPF) on at least 1 esophageal biopsy and when other causes such as proton pump inhibitor (PPI)- responsive esophageal eosinophilia are excluded (Dellon et al., 2014a: Furuta et al., 2007).

The standards of care are diet therapies and off-label use of glucocorticosteroids. Esophageal dilation is used to temporarily relieve symptoms but does not address underlying inflammation. Given the clinical outcomes associated with EoE , including severe dysphagia, esophageal stricture, food impaction, and esophageal perforation (Hirano and Aceves, 2014; Liacouras et al., 2011) and the fact that there are currently no FDA approved treatments, there is a clear unmet medical need for a novel treatment for this disease.

Click to learn more about Eosinophilic Esophagitis

 

We are currently conducting a clinical trial for patients with Eosinophilic Esophagitis.

To be included, participants must:

  • Be between the ages of 18-55
  • Suffer from any of these: eating problems, abdominal pain, heartburn, trouble swallowing, vomiting, or food impaction
  • Have taken medication for heartburn and has not helped

If you meet these criteria, then you may be eligible to participate in our study.

Click here for clinical trials details (clinicaltrials.gov).

Share This: